CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Oxybutynin Chloride Gel

Last Updated: October 25, 2011
Result type: Reports
Project Number: SR0260-000
Product Line: Reimbursement Review

Generic Name: Oxybutynin Chloride Gel

Brand Name: Gelnique

Manufacturer: Watson Pharma Company

Therapeutic Area: Overactive bladder

Indications: Bladder, overactive

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 24, 2012

Recommendation Type: Do not list